Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s ...

NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome ("GI-ARS"), after the ...

The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...

Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, ...

Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the ...

Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET.

Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range ...

FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not ...

TOKYO-- (BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ...

Early-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting ...

Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals ...

Net Income and Diluted Net Income Per Share: GAAP net income was $275.1 million, or $0.72 per diluted share, for the third ...